A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity

References

1. 1.↵
   2. Siegel RL,
   3. Miller KD,
   4. Fuchs HE,
   5. Jemal A.

   Cancer statistics, 2022. CA Cancer J Clin. 2022; 72: 7–33.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Geoerger B,
   3. Kang HJ,
   4. Yalon-Oren M,
   5. Marshall LV,
   6. Vezina C,
   7. Pappo A, et al.

   Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020; 21: 121–33.

   OpenUrlCrossRefPubMed
3. 3.
   2. Goldberg SB,
   3. Schalper KA,
   4. Gettinger SN,
   5. Mahajan A,
   6. Herbst RS,
   7. Chiang AC, et al.

   Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020; 21: 655–63.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Balar AV,
   3. Galsky MD,
   4. Rosenberg JE,
   5. Powles T,
   6. Petrylak DP,
   7. Bellmunt J, et al.

   Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389: 67–76.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Mittendorf EA,
   3. Zhang H,
   4. Barrios CH,
   5. Saji S,
   6. Jung KH,
   7. Hegg R, et al.

   Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020; 396: 1090–100.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Schmid P,
   3. Rugo HS,
   4. Adams S,
   5. Schneeweiss A,
   6. Barrios CH,
   7. Iwata H, et al.

   Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21: 44–59.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Adams S,
   3. Gray RJ,
   4. Demaria S,
   5. Goldstein L,
   6. Perez EA,
   7. Shulman LN, et al.

   Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32: 2959–66.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Denkert C,
   3. von Minckwitz G,
   4. Darb-Esfahani S,
   5. Lederer B,
   6. Heppner BI,
   7. Weber KE, et al.

   Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018; 19: 40–50.

   OpenUrlPubMed
9. 9.↵
   2. Wang M,
   3. Pang Z,
   4. Wang Y,
   5. Cui M,
   6. Yao L,
   7. Li S, et al.

   An immune model to predict prognosis of breast cancer patients receiving neoadjuvant chemotherapy based on support vector machine. Front Oncol. 2021; 11: 651809.
10. 10.↵
    2. Cortazar P,
    3. Zhang L,
    4. Untch M,
    5. Mehta K,
    6. Costantino JP,
    7. Wolmark N, et al.

    Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (Lond, Engl). 2014; 384: 164–72.

    OpenUrl
11. 11.↵
    2. Jakobsen JC,
    3. Gluud C,
    4. Wetterslev J,
    5. Winkel P.

    When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017; 17: 162.

    OpenUrlCrossRefPubMed
12. 12.
    2. Mellenbergh GJ,
    3. Adèr HJ

    2. Lodder P.

    To impute or not impute: that’s the question. In: Mellenbergh GJ, Adèr HJ, eds. Advising on research methods: selected topics 2013. Huizen, The Netherlands: Johannes van Kessel Publishing; 2014.
13. 13.↵
    2. Schmitt P,
    3. Mandel J,
    4. Guedj M.

    A comparison of six methods for missing data imputation. J Biomet Biostat. 2015; 6: 224.000.
14. 14.↵
    2. Torgo L.

    Data mining with R learning with case studies. 2^nd ed. Chapman and Hall/CRC; 2016.
15. 15.↵
    2. Were K,
    3. Bui DT,
    4. Dick ØB,
    5. Singh BR.

    A comparative assessment of support vector regression, artificial neural networks, and random forests for predicting and mapping soil organic carbon stocks across an Afromontane landscape. Ecol Indic. 2015; 52: 394–403.

    OpenUrl
16. 16.↵
    2. Kuhn M,
    3. Wing J,
    4. Weston S,
    5. Williams A,
    6. Keefer C,
    7. Engelhardt A, et al.

    Caret: Classification and Regression Training; 2016. https://CRAN.R-project.org/package=caret.
17. 17.↵
    2. Liaw A,
    3. Wiener M.

    Classification and regression by randomForest. R News. 2002; 2: 18–22.

    OpenUrlCrossRef
18. 18.↵
    2. Robin X,
    3. Turck N,
    4. Hainard A,
    5. Tiberti N,
    6. Lisacek F,
    7. Sanchez JC, et al.

    pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12: 77.

    OpenUrlCrossRefPubMed
19. 19.↵
    2. Harrell FE Jr..

    Regression modeling strategies. 2022.
20. 20.↵
    2. Sigal MJ,
    3. Chalmers RP.

    Play it again: teaching statistics with Monte Carlo simulation. J Stat Educ. 2016; 24: 136–56.

    OpenUrlCrossRef
21. 21.↵
    2. Batista GEAPA,
    3. Prati RC,
    4. Monard MC.

    A study of the behavior of several methods for balancing machine learning training data. SIGKDD Explor Newsl. 2004; 6: 20–9.

    OpenUrl
22. 22.↵
    2. Fang F,
    3. Wang W,
    4. Chen M,
    5. Tian Z,
    6. Xiao W.

    Technical advances in NK cell-based cellular immunotherapy. Cancer Biol Med. 2019; 16: 647–54.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    2. Myers JA,
    3. Miller JS.

    Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021; 18: 85–100.

    OpenUrlCrossRefPubMed
24. 24.↵
    2. Norton L.

    Conceptual basis for advances in the systemic drug therapy of breast cancer. Semin Oncol. 1997; 24: S11-2–S11-12.

    OpenUrlPubMed
25. 25.↵
    2. Muntasell A,
    3. Rojo F,
    4. Servitja S,
    5. Rubio-Perez C,
    6. Cabo M,
    7. Tamborero D, et al.

    NK cell infiltrates and HLA class I expression in primary HER2(+) breast cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res. 2019; 25: 1535–5.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    2. Chen DS,
    3. Mellman I.

    Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39: 1–10.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    2. Schmid P,
    3. Cortes J,
    4. Pusztai L,
    5. McArthur H,
    6. Kümmel S,
    7. Bergh J, et al.

    Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020; 382: 810–21.

    OpenUrlCrossRefPubMed
28. 28.↵
    2. Xie G,
    3. Dong H,
    4. Liang Y,
    5. Ham JD,
    6. Rizwan R,
    7. Chen J.

    CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020; 59: 102975.
29. 29.↵
    2. Chan IS,
    3. Knútsdóttir H,
    4. Ramakrishnan G,
    5. Padmanaban V,
    6. Warrier M,
    7. Ramirez JC, et al.

    Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol. 2020; 219: e202001134.
30. 30.↵
    2. Yu M,
    3. Pan H,
    4. Che N,
    5. Li L,
    6. Wang C,
    7. Wang Y, et al.

    Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells. Cell Mol Immunol. 2021; 18: 2153–64.

    OpenUrl
31. 31.↵
    2. Slattery K,
    3. Woods E,
    4. Zaiatz-Bittencourt V,
    5. Marks S,
    6. Chew S,
    7. Conroy M, et al.

    TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer. J Immunother Cancer. 2021; 9: e002044.